cc-8k_20190430.htm

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF

THE SECURITIES EXCHANGE ACT OF 1934

 

April 30, 2019

Date of Report (Date of Earliest Event Reported)

The Chemours Company

(Exact Name of Registrant as Specified in Its Charter)

 

Delaware

 

001-36794

 

46-4845564

(State or Other Jurisdiction

 

(Commission

 

(I.R.S. Employer

Of Incorporation)

 

File Number)

 

Identification No.)

 

1007 Market Street

Wilmington, Delaware, 19899

(Address of principal executive offices)

 

Registrant’s telephone number, including area code: (302) 773-1000

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

 

 

 

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

 

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of Each Class

 

Trading Symbol(s)

 

Name of Exchange on Which Registered

Common Stock ($.01 par value)

 

CC

 

New York Stock Exchange

 

 

 

 

 


 

 

Item 5.07Submission of Matters to a Vote of Security Holders.

 

The Chemours Company held its annual meeting of shareholders on April 30, 2019 (the “Annual Meeting”).

 

At the Annual Meeting, shareholders voted:

 

 

in favor of the election of all eight director nominees;

 

in favor of the advisory “say-on-pay” vote;

 

in favor of ratifying PricewaterhouseCoopers LLP; and

 

against the shareholder proposal.

 

The final voting results were as follows:

 

Proposal 1 – Election of Directors to Serve One-Year Terms Expiring at the Annual Meeting of Shareholders in 2020

 

Nominee

For

Against

Abstain

Total

Broker Non-Votes

Curtis V. Anastasio

128,495,713

(99.36%)

521,334

313,350

129,330,397

22,596,043

Bradley J. Bell

127,559,273

(98.63%)

1,460,772

310,353

129,330,398

22,596,042

Richard H. Brown

128,630,717

(99.46%)

381,990

317,691

129,330,398

22,596,042

Mary B. Cranston

127,436,310

(98.54%)

1,555,634

338,458

129,330,402

22,596,038

Curtis J. Crawford

126,524,666

(97.83%)

2,489,399

316,330

129,330,395

22,596,045

Dawn L. Farrell

127,605,954

(98.67%)

1,416,176

308,273

129,330,403

22,596,037

Sean D. Keohane

127,660,240

(98.71%)

1,368,111

302,052

129,330,403

22,596,037

Mark P. Vergnano

128,675,778

(99.49%)

339,681

314,939

129,330,398

22,596,042

 

Proposal 2 – Advisory Vote to Approve Named Executive Officer Compensation

 

For

Against

Abstain

Total

Broker Non-Votes

122,836,702

(94.98%)

5,914,855

578,827

129,330,384

22,596,056

 

Proposal 3 – Ratification of Selection of PricewaterhouseCoopers LLP for Fiscal Year 2019

 

For

Against

Abstain

Total

Broker Non-Votes

150,960,667

(99.36%)

553,965

411,808

151,926,440

n/a

 

Proposal 4 – Shareholder proposal for a report on executive compensation

 

For

Against

Abstain

Total

Broker Non-Votes

5,465,901

(4.23%)

122,015,133

1,849,348

129,330,382

22,596,058

 

 

 

 


 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

THE CHEMOURS COMPANY

 

By:

 

/s/ Mark E. Newman

 

 

Mark E. Newman

 

 

Senior Vice President and

 

 

Chief Financial Officer

 

Date:

 

May 3, 2019